Navigation Links
Understand the Lessons Learned from the FDA QbD Pilot Programme - Case Study Merck Serono
Date:2/15/2012

LONDON, February 15, 2012 /PRNewswire/ --

Senior representatives from leading pharmaceutical companies including Roche Diagnostics, Lonza, Abbott, F. Hoffman-La-Roche LTD and Novartis MIT will meet at the Pharma Qbd Forum in Berlin, Germany on 24th-25th April 2012 to share their expert knowledge on how Quality by Design can be implemented in pharmaceutical development.

One of the main points of discussion will be the findings of the Merck Serono case study and how the lessons learned from this FDA Pilot Programme can shape the way for QbD projects in Europe and abroad. This session will be led by Pascal Valax, Group Head, Biotech Process Sciences, Merck Serono SA.

Speakers include:

  • Dr. John R Donaubauer, Director, Scientific Affairs Development Sciences Process R&D - Abbott
  • Dr.Richard Lakerveld, Associate - Novartis-MIT Center for Continuous Manufacturing
  • Serj Vartanian, Head of Global Quality Systems MBB - Baxter Healthcare Corporation
  • Dr. Gawayne Mahboubian-Jones, Program head - Excellence in Science and Design - Philip Morris International
  • Dr.Paul Stonestreet, Global Drug Substance Project Co-ordinator, Small Molecule Technical Development - F.Hoffman-La-Roche Ltd
  • Dr. Dirk Pamperin, VP R&D - Synthon Pharmaceuticals
  • Dr. Alessandro Butte, Head of DSP - Lonza
  • Sarah Mercier, Scientist USP - Crucell Holland BV
  • Dr. John Crowley, Head of Cell Culture Development - Lonza Biologics
  • Dr. Andreas Schneider, Vice President Life Science Alliances - Roche Diagnostics
  • Prof. Gary Montague, Professor of Bioprocess Control - Newcastle University
  • Dr. Mel Koch, Executive Director - CPAC Centre for Process and Analytical Control (University of Washington)
  • Prof. Mathieu Streefland, Professor Bioprocess Engineering - Wageningen University
  • Prof. Jose Cardoso de Menezes, Department of BioEngineering - Institute of Biotechnology & Bioengineering

Conference topics include:

  • Building quality earlier in the process
  • Improving process understanding
  • Successfully defining criticality
  • Defining continuous verification and the expanded change protocol
  • Lifecycle strategies for biopharmaceutical QbD
  • Implementing continuous manufacturing with QbD to reduce production timelines
  • Translating established development practice into QbD

To view the complete programme, speakers and topics visit http://www.pharmaqbdforum.com

For all press enquiries, email sarah.brzezicki@wtgevents.com or telephone +44(0)207-202-7727.



'/>"/>
SOURCE World Trade Group Conferences
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amerigen Pharmaceuticals and VIWA Pharmaceutical Company Today Jointly Announce the Signing of a Memorandum of Understanding (MOU) Setting Out Their Intention to Establish a Joint Venture to Develop and Register a Range of Branded Generic Medicines
2. HIFU All Hype? Understanding This Non-FDA-Approved Prostate Cancer Treatment
3. Team AFib™ Unites Patient Advocacy Organizations to Elevate Understanding of Atrial Fibrillation and Stroke
4. Aeras and China National Biotech Group Sign Memorandum of Understanding for TB Vaccine R&D Collaboration
5. American Pain Foundation Launches New Educational Campaign, "Explain Your Pain," to Help Hispanic Americans Better Understand Chronic Pain and Pain Management
6. FDA Examines Ways to Improve Consumer Understanding of Prescription Drug Ads
7. Genoptix Enters Into Memorandum of Understanding Related to Class Action Lawsuits
8. Ground Breaking Findings on Understanding Cancer Published in the Current Issue of Science
9. Decision Resources Competitive Landscape Seminar Series: Biologics and Biosimilars on September 14, 2010 Will Help Pharmaceutical Companies Understand Market Opportunities for Biologics and Biosimilars
10. Information-Motivation-Behavioral Skills Analysis Advances Understanding of Barriers to Self-Monitoring of Blood Glucose
11. Results From Two Phase II Trials Add to Understanding of Ticagrelor (BRILINTA(TM)) and How it Works in the Body
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... and TORONTO , March 28, 2017 ... leading full service medical device development firm, announced today ... Toronto -based medical device industrial design ... serve medtech companies throughout North America ... experienced medical device talent spanning the design, engineering, regulatory, ...
(Date:3/28/2017)... United Kingdom and  BOSTON , March 28, ... Linguamatics today announced a partnership with ... The agreement allows pharmaceutical companies to extract key ... I2E text mining technology. The ... of the top 20 global pharmaceutical companies. The ...
(Date:3/28/2017)... , March 28, 2017 Emosis SAS, ... new business entity, Emosis Ltd, headquartered in Tel Aviv ... novel assays complementing the mother company existing technology platform and test ... sales development of Emosis kits. ... This strategic move starts building Emosis international footprint. Emosis ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... 2017 , ... Resoundant, Inc., the developer of Magnetic ... annual customer education symposium, a world-class learning conference that offers educational content designed ... 31, 2017 at the Atlanta Marriott Marquis in Atlanta, Georgia. , Innovations for ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... of all holidays (IBT World Travel Trends Report). As travelers visit both urban ... range in temperatures, and prolonged sun exposure. In response, the outdoor industry has ...
(Date:3/28/2017)... ... ... Alert Sentry Group LLC., a leader in the Personal Emergency Response System industry, introduced ... Plus. These iSAFE products are the most affordable and most advanced medical alert systems ... direct GPS Location and two-way calling with the push of a button on a ...
(Date:3/28/2017)... ... , ... The Radiology Business Management Association (RBMA) is pleased to ... executive director. Mr. Still was selected through a careful months-long search by the RBMA ... known to our members, has been a part of building the RBMA since 1992,” ...
(Date:3/28/2017)... ... March 28, 2017 , ... Neurotechnology , a provider ... and attendance tracking products: the new NCheck Cloud Bio Attendance cloud-based service and ... biometric face recognition to enable users to check in and out from anywhere ...
Breaking Medicine News(10 mins):